Pharmacokinetics and Exposure–Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease

Documenti analoghi

• Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure–Response Models, and Real‐World Patient Data
  di: Yuli Qian, et al.
  Pubblicazione: (2024)
• Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis
  di: Neha Thakre, et al.
  Pubblicazione: (2024)
• Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults
  di: Jaime Algorta, et al.
  Pubblicazione: (2024)
• Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure‐Response Analysis
  di: Xiaofei Zhou, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis
  di: Benjamin Rich, et al.
  Pubblicazione: (2025)